Patents Assigned to Hospices Civils de Lyon
-
Publication number: 20240011092Abstract: The subject matter is a method for determining the proliferation capacity of T lymphocytes in a subject, the method including the following steps: a) measuring the load of torque teno virus from a biological sample of the subject; and b) determining the proliferative capacity of the T lymphocytes based on the viral load measured in a).Type: ApplicationFiled: November 4, 2021Publication date: January 11, 2024Applicants: BIOMERIEUX, HOSPICES CIVILS DE LYON, UNIVERSITÉ CLAUDE BERNARD LYON 1Inventors: Karen BRENGEL-PESCE, Sophie ASSANT-TROUILLET, William MOUTON
-
Patent number: 11693003Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.Type: GrantFiled: April 24, 2017Date of Patent: July 4, 2023Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio ScientificInventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
-
Publication number: 20230194549Abstract: An in vitro or ex vivo method, based on the measurement of the expression of cytokine(s), from a patient's blood sample, incubated with a stimulus, for determining the risk of occurrence of a healthcare-associated infection in the patient, within seven days following the day on which the collection of the biological sample has been performed from the patient.Type: ApplicationFiled: April 8, 2021Publication date: June 22, 2023Applicants: BIOMÉRIEUX, BIOASTER, HOSPICES CIVILS DE LYONInventors: François MALLET, Guillaume MONNERET, Virginie MOUCADEL, Alexandre PACHOT, Estelle PERONNET, Julien TEXTORIS, Fabienne VENET, Thomas RIMMELÉ
-
Patent number: 11630101Abstract: The present invention relates to a method for diagnosing anomalies in the coagulation of blood, comprising the following successive steps: a) placing a sample of total blood in a holder containing two pairs of electrodes connected to an apparatus generating an electrical current; b) incubating this sample for 60 to 180 seconds in the presence of calcium; c) adding to this sample tissue factor in a concentration high enough to trigger the coagulation of the blood; d) measuring the impedance variation between the electrodes as a function of time, for a period comprised between 10 and 30 minutes from step (c), and generating a curve of the impedance values as a function of time; e) comparing the value of the area under the curve generated in step (d) with the value of an area under a reference curve.Type: GrantFiled: November 15, 2016Date of Patent: April 18, 2023Assignee: HOSPICES CIVILS DE LYONInventor: Christophe Nougier
-
Patent number: 11555191Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.Type: GrantFiled: August 31, 2018Date of Patent: January 17, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, CENTRE LÉON-BÉRARD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ CLAUDE BERNARD LYON 1Inventors: Jean Pierre Quivy, Barbara Testoni, Fabien Zoulim, Maelle Locatelli
-
Publication number: 20220390458Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.Type: ApplicationFiled: September 22, 2020Publication date: December 8, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, CPE LYON FORMATION CONTINUE ET RECHERCHE pouvant être précédée ou suivie par CPE LYON FCR, CENTRE LEON BERARD, HOSPICES CIVILS DE LYONInventors: Thierry GRANJON, Ofelia MANITI, Olivier MARCILLAT, Peter GOEKJIAN, Mouhedine CHENIOUR, Arnaud VIGNERON, David GUEYRARD, Sébastien IBANEZ
-
Publication number: 20220381791Abstract: An in vitro or ex vivo method for determining the ability of an individual to respond to a stimulus, based on the measurement of the expression of at least two different biomarkers, selected from different lists among three lists of biomarkers, from a blood sample of the individual, incubated with the stimulus, as well as tools allowing the implementation of this method and the use of these tools.Type: ApplicationFiled: September 30, 2020Publication date: December 1, 2022Applicants: BIOMÉRIEUX, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Sophie ASSANT, François MALLET, François BARTOLO, Chloé ALBERT VEGA
-
Publication number: 20220348587Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.Type: ApplicationFiled: June 3, 2022Publication date: November 3, 2022Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
-
Publication number: 20220333201Abstract: An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.Type: ApplicationFiled: September 25, 2020Publication date: October 20, 2022Applicants: BIOMÉRIEUX, BIOASTER, HOSPICES CIVILS DE LYONInventors: Laurence VACHOT, François MALLET, Guillaume MONNERET, Virginie MOUCADEL, Alexandre PACHOT, Estelle PERONNET, Thomas RIMMELÉ, Julien TEXTORIS, Fabienne VENET
-
Patent number: 11459605Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.Type: GrantFiled: December 18, 2012Date of Patent: October 4, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: François Mallet, Nathalie Mugnier, Philippe Perot
-
Patent number: 11453916Abstract: The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.Type: GrantFiled: December 17, 2012Date of Patent: September 27, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: François Mallet, Nathalie Mugnier, Philippe Perot
-
Publication number: 20220259661Abstract: A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.Type: ApplicationFiled: April 26, 2022Publication date: August 18, 2022Applicants: BIOMERIEUX, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Elisabeth CERRATO, Benjamin DELWARDE, Guillaume MONNERET, Estelle PERONNET, Julien TEXTORIS, Fabienne VENET
-
Patent number: 11384081Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.Type: GrantFiled: September 20, 2017Date of Patent: July 12, 2022Assignees: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Toufic Renno, Isabelle Coste-Invernizzi, Stéphane Giraud, Serge Lebecque
-
Patent number: 11377690Abstract: The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.Type: GrantFiled: January 10, 2014Date of Patent: July 5, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: Marie-Angelique Cazalis, Maud Tournoud, Fabienne Venet, Alain Lepape, Guillaume Monneret
-
Publication number: 20220178949Abstract: The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.Type: ApplicationFiled: May 2, 2019Publication date: June 9, 2022Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Le Duy DO, Jérôme HONNORAT, Véronique ROGEMOND
-
Patent number: 11351180Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.Type: GrantFiled: March 18, 2016Date of Patent: June 7, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
-
Patent number: 11339438Abstract: The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient. The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.Type: GrantFiled: December 1, 2016Date of Patent: May 24, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BENARD LYON 1Inventors: Elisabeth Cerrato, Benjamin Delwarde, Guillaume Monneret, Estelle Peronnet, Julien Textoris, Fabienne Venet
-
Publication number: 20220119893Abstract: The invention relates to an in vitro process for classifying a glioma, comprising the following steps: a. Measuring at least, from a glioma patient biological sample, the Alternative Lengthening of Telomeres (ALT) status of said glioma; b. Optionally, determining the isocitrate dehydrogenase genes mutation status (IDH status) of said glioma; c. Based on the data obtained in steps (a) and optionally (b) and, if available, on the histological grade of said glioma, classifying said glioma in one of the five following classes: oligodendroglioma-like, glioblastoma IDHwt-like, glioblastoma IDHmt-like, low-grade astrocytoma-like, and other gliomas.Type: ApplicationFiled: February 19, 2020Publication date: April 21, 2022Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventor: Delphine PONCET
-
Patent number: 11299768Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.Type: GrantFiled: January 18, 2010Date of Patent: April 12, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: Marie-Angelique Cazalis, Alain Lepape, Guillaume Monneret, Bruno Mougin, Alexandre Pachot
-
Publication number: 20220007620Abstract: The present invention relates to an avian model enabling the amplification of human or animal circulating tumour cells (CTC) and to the use thereof for monitoring and determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s), as well as for screening novel therapeutic agents intended for the treatment of cancer.Type: ApplicationFiled: October 29, 2019Publication date: January 13, 2022Applicants: INOVOTION, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Xavier ROUSSET, Emilien DOSDA, Jean VIALLET, Léa PAYEN-GAY, Denis MAILLET